BRPI0413574A - aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer - Google Patents

aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer

Info

Publication number
BRPI0413574A
BRPI0413574A BRPI0413574-1A BRPI0413574A BRPI0413574A BR PI0413574 A BRPI0413574 A BR PI0413574A BR PI0413574 A BRPI0413574 A BR PI0413574A BR PI0413574 A BRPI0413574 A BR PI0413574A
Authority
BR
Brazil
Prior art keywords
application
cancer therapy
cytotoxic factors
family polypeptides
methods
Prior art date
Application number
BRPI0413574-1A
Other languages
English (en)
Inventor
Amanda M Chakrabarty
Tapas K Das Gupta
Vasu Punj
Olga Zaborina
Yoshinori Hiraoka
Tohru Yamada
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BRPI0413574A publication Critical patent/BRPI0413574A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"APLICAçãO DE POLIPEPTìDEOS DA FAMìLIA CUPREDOXINA NA TERAPIA DO CáNCER". São revelados fatores citotóxicos tendo aplicação na modulação da morte celular, e sua aplicação em métodos para tratar condições relacionadas com necroses ou apoptose. A invenção também refere-se a métodos para identificar agentes ativos úteis para tratar condições relacionadas com morte celular ou crescimento descontrolado. Os inventores presentes descobriram que diferentes microorganismos produzem diferentes fatores citotóxicos tendo atividade anticancerígena. Os fatores citotóxicos essencialmente puros podem ser usados em um método para tratar uma doença infecciosa ou um câncer.
BRPI0413574-1A 2003-08-15 2004-08-10 aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer BRPI0413574A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41455003P 2003-08-15 2003-08-15
US10/720,603 US7491394B2 (en) 2001-02-15 2003-11-24 Cytotoxic factors for modulating cell death
PCT/US2004/025982 WO2005018662A1 (en) 2003-08-15 2004-08-10 Use of polypeptides of the cupredoxin family in cancer therapy

Publications (1)

Publication Number Publication Date
BRPI0413574A true BRPI0413574A (pt) 2006-10-17

Family

ID=34221130

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413574-1A BRPI0413574A (pt) 2003-08-15 2004-08-10 aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer

Country Status (19)

Country Link
US (4) US7491394B2 (pt)
EP (2) EP2263682A1 (pt)
JP (1) JP2007502818A (pt)
KR (1) KR20060098358A (pt)
AP (1) AP2006003537A0 (pt)
AT (1) ATE470672T1 (pt)
AU (1) AU2004266632A1 (pt)
BR (1) BRPI0413574A (pt)
CA (1) CA2535581A1 (pt)
DE (1) DE602004027637D1 (pt)
EA (1) EA009897B1 (pt)
EC (1) ECSP066422A (pt)
GE (1) GEP20105022B (pt)
IL (1) IL173576A0 (pt)
NO (1) NO20061168L (pt)
NZ (1) NZ545355A (pt)
OA (1) OA13308A (pt)
TN (1) TNSN06059A1 (pt)
WO (1) WO2005018662A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7618939B2 (en) 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
EP1883650A4 (en) * 2005-05-20 2009-06-10 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING HIV INFECTION USING CUPREDOXIN AND CYTOCHROME C
AU2006277009A1 (en) * 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
EP1882039A4 (en) * 2005-05-20 2008-08-20 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING MALARIA USING CUPREDOXINS AND CYTOCHROMES
WO2007024368A2 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
CA2615617A1 (en) * 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
US10266868B2 (en) 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
JP2010502765A (ja) * 2006-09-11 2010-01-28 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ キュプレドキシン由来ペプチドの修飾及びそれを使用する方法
EP2061498A4 (en) * 2006-09-14 2009-11-04 Univ Illinois COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES
JP2010511408A (ja) * 2006-12-04 2010-04-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
EP2117573A4 (en) * 2007-01-11 2011-02-16 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES AND MUTANTS THEREOF
JP2010518123A (ja) * 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をキュプレドキシンで予防するための組成物および方法
MY160424A (en) * 2008-09-18 2017-03-15 Hoffmann La Roche Substituted pyrrolidine-2-carboxyamides.
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
DK3234107T3 (da) 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
WO2016176573A1 (en) * 2015-04-30 2016-11-03 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
CN111705026B (zh) * 2020-06-02 2021-11-26 华中农业大学 一种牛支原体Mbov_0280基因突变株及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585644A (en) 1984-06-04 1986-04-29 Phillips Petroleum Company Changing oil tubes in a carbon black reactor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
JP4881536B2 (ja) 2001-02-15 2012-02-22 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 細胞死を調節する細胞障害性因子
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CN1863545A (zh) 2003-08-15 2006-11-15 伊利诺斯大学理事会 Cupredoxin家族多肽在癌症治疗中的用途
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
EP1883650A4 (en) 2005-05-20 2009-06-10 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING HIV INFECTION USING CUPREDOXIN AND CYTOCHROME C
EP1882039A4 (en) 2005-05-20 2008-08-20 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING MALARIA USING CUPREDOXINS AND CYTOCHROMES
CA2615617A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof

Also Published As

Publication number Publication date
EP2263682A1 (en) 2010-12-22
TNSN06059A1 (en) 2007-10-03
US20060292136A1 (en) 2006-12-28
IL173576A0 (en) 2006-07-05
DE602004027637D1 (de) 2010-07-22
EA009897B1 (ru) 2008-04-28
US20080182782A1 (en) 2008-07-31
EP1653990A1 (en) 2006-05-10
US7888468B2 (en) 2011-02-15
AU2004266632A1 (en) 2005-03-03
WO2005018662A1 (en) 2005-03-03
OA13308A (en) 2007-04-13
US20140179617A1 (en) 2014-06-26
US20060040269A1 (en) 2006-02-23
GEP20105022B (en) 2010-06-25
KR20060098358A (ko) 2006-09-18
US7491394B2 (en) 2009-02-17
EA200600424A1 (ru) 2006-08-25
JP2007502818A (ja) 2007-02-15
US10421801B2 (en) 2019-09-24
CA2535581A1 (en) 2005-03-03
ECSP066422A (es) 2006-11-24
EP1653990B1 (en) 2010-06-09
NZ545355A (en) 2009-10-30
ATE470672T1 (de) 2010-06-15
NO20061168L (no) 2006-05-15
AP2006003537A0 (en) 2006-04-30

Similar Documents

Publication Publication Date Title
BRPI0413574A (pt) aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
BR0110420A (pt) Agonistas muscarìnicos
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
GEP20022804B (en) Erythropoietin Derivatives
ATE200085T1 (de) Histidine und homohistidine derivate zur verwendung als protein farnesyltransferase hemmstoffe
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
NO20025450D0 (no) Ny farmasöytisk sammensetning
DK155143C (da) Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet
BRPI0408256A (pt) composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
BRPI0414215A (pt) tienopirazóis
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
ATE461707T1 (de) Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
DE69934987D1 (de) Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
WO2024026308A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
BR0311371A (pt) Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento
ATE406158T1 (de) Verwendung von vitamin c zur behandlung der charcot-marie-tooth krankheit
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014.